Related Experiment Video
Updated: Mar 31, 2026
02:28
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
1.0K
Apremilast in psoriatic arthritis
1Department of Internal Medicine 3, University of Erlangen-Nuremberg Erlangen, Germany. georg.schett@uk-erlangen.de.
Clinical and Experimental Rheumatology
|October 17, 2015
Summary
Apremilast effectively treats psoriatic arthritis and skin disease by inhibiting phosphodiesterase 4 (PDE4). This mechanism increases cAMP levels, reducing inflammatory cytokines and improving patient outcomes.
Area of Science:
- Immunology
- Pharmacology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition affecting joints and skin.
- Current treatments aim to manage inflammation and improve patient quality of life.
Purpose of the Study:
- To summarize the efficacy and safety of apremilast for treating psoriatic arthritis.
- To elucidate the mechanism of action of apremilast in PsA.
Main Methods:
- Review of four phase III clinical trials.
- Pharmacological analysis of apremilast's mechanism.
Main Results:
- Apremilast demonstrated efficacy and safety in moderate to severe PsA.
- The drug is approved in the US and Europe for PsA treatment.
- Apremilast also shows benefits for psoriatic skin disease.
Conclusions:
- Apremilast is a valuable therapeutic option for PsA.
- Its mechanism involves PDE4 inhibition, leading to increased cAMP and reduced pro-inflammatory cytokines.
- This results in clinical improvement for patients with PsA and psoriatic skin disease.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
608
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
01:20Asthma: Pathogenesis and Management
1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K